Protagonist Q3 net loss $34.1M; earns $50M milestone from Janssen for JNJ-2113 Phase 3

Protagonist Therapeutics, Inc

2023-Q3 EPS reported -$1.91

Net loss of $34.1M ($0.58 per share) vs $31.2M loss in Q3 2022; R&D expenses rose to $30.7M.
Cash, equivalents and marketable securities $322.7M as of Sep 30, 2023; cash runway through Q1 2026.
JNJ-2113 Phase 3 ICONIC-LEAD, ICONIC-TOTAL trials and Phase 2b ANTHEM-UC trial initiated in Q4 2023.
Dosing of third patient in ICONIC-LEAD triggered $50M milestone from Janssen in October 2023.
Five rusfertide abstracts accepted for oral/poster presentations at ASH 2023 annual meeting.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Protagonist Therapeutics, Inc reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 2, 2023, Protagonist Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-113828

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.